Special Issue "Plant Expression Systems for Bioproduct Production"

A special issue of Plants (ISSN 2223-7747).

Deadline for manuscript submissions: 31 December 2019.

Special Issue Editor

Dr. Hyun-Soon Kim
E-Mail
Guest Editor
Plant Systems Engineering Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea
Interests: plant biotechnology; plant gene expression; high level expression vector ; plant molecular farming; plant-derived vaccine, biopharmaceutical; plant-based edible vaccine; virus-like particle

Special Issue Information

Dear Colleagues,

Plant-based expression systems for bioproducts, including recombinant pharmaceutical proteins, have emerged as an acceptable alternative to conventional expression platforms such as bacterial, yeast, and animal cell. The benefits or advantages cited most often are rapid scalability with transgenic plants or transient expression, higher stability of recombinant proteins, safety due to lack of harmful substances, and capability of producing proteins with desired post-translational modifications.

Due to several significant events, such as ElelysoTM (Protalix, Carmiel, Israel), non-Hodgkin’s lymphoma vaccines (Large Scale Biology, Icon Genetics/Bayer, Halle, Germany), the influenza serotype H1N1 and H5N1 vaccines (Fraunhofer CMB, Newark, DE, and Medicago, Quebec, QC, Canada), and ZMappTM cocktail (Mapp Biotherapeutics, San Diego, CA), readers around the world have become very interested in this plant molecular farming area.

Plant expression systems still have several limitations to be overcome to improve protein yields/quality. The level of protein expression is a critical factor in plant molecular farming, and this level varies according to the plant species and the organs involved and target protein of interest. The expression/production of recombinant native and engineered proteins is a complicated procedure that requires an inter- and multi-disciplinary effort including immunology, genomics, bioinformatics, protein structure, etc. Possible topics in this issue cover research in important plant resources, affecting factors, and the recombinant-protein expression techniques relevant to the plant molecular farming process. Further, this Special Issue will highlight recent advances that have been achieved in plant-based bioproduct production platforms in terms of expression strategies, product yields, and downstream processing development. 

I wish to thank all authors for their contributions to this Special issue.

Dr. Hyun-Soon Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Plants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • plant-based expression system
  • molecular farming/pharming
  • recombinant protein
  • biopharmaceuticals
  • bioproduct
  • gene expression
  • transgenic plant
  • transient expression

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Recombinant Human Dentin Matrix Protein 1 (hDMP1) Expressed in Nicotiana benthamiana Potentially Induces Osteogenic Differentiation
Plants 2019, 8(12), 566; https://doi.org/10.3390/plants8120566 - 03 Dec 2019
Abstract
Inductive molecules are critical components for successful bone tissue engineering. Dentin matrix protein-1 (DMP1), a non-collagenous protein in the bone matrix, has been shown to play roles in osteogenic differentiation and phosphate homeostasis. This study aimed to produce recombinant human dentin matrix protein-1 [...] Read more.
Inductive molecules are critical components for successful bone tissue engineering. Dentin matrix protein-1 (DMP1), a non-collagenous protein in the bone matrix, has been shown to play roles in osteogenic differentiation and phosphate homeostasis. This study aimed to produce recombinant human dentin matrix protein-1 (hDMP1) in Nicotiana benthamiana and investigated the ability of this plant-produced DMP1 to induce osteogenesis in human periodontal ligament stem cells (hPDLSCs). The hDMP1 gene was cloned into the geminiviral vector for transient expression in N. benthamiana. We found that hDMP1 was transiently expressed in N. benthamiana leaves and could be purified by ammonium sulphate precipitation followed by nickel affinity chromatography. The effects of hDMP1 on the induction of cell proliferation and osteogenic differentiation were investigated. The results indicated that plant-produced hDMP1 could induce the cell proliferation of hPDLSCs and increase the expression levels of osteogenic genes, including osterix (OSX), type I collagen (COL1), bone morphogenetic protein-2 (BMP2), and Wnt3a. Moreover, the plant-produced hDMP1 promoted calcium deposition in hPDLSCs as determined by alizarin red S staining. In conclusion, our results indicated that plant-produced hDMP1 could induce osteogenic differentiation in hPDLSCs and could potentially be used as a bone inducer in bone tissue engineering. Full article
(This article belongs to the Special Issue Plant Expression Systems for Bioproduct Production)
Open AccessArticle
Plant-Produced Anti-Enterovirus 71 (EV71) Monoclonal Antibody Efficiently Protects Mice Against EV71 Infection
Plants 2019, 8(12), 560; https://doi.org/10.3390/plants8120560 - 01 Dec 2019
Abstract
Enterovirus 71 (EV71) is the main causative agent of severe hand-foot-mouth disease. EV71 affects countries mainly in the Asia-Pacific region, which makes it unattractive for pharmaceutical companies to develop drugs or vaccine to combat EV71 infection. However, development of these drugs and vaccines [...] Read more.
Enterovirus 71 (EV71) is the main causative agent of severe hand-foot-mouth disease. EV71 affects countries mainly in the Asia-Pacific region, which makes it unattractive for pharmaceutical companies to develop drugs or vaccine to combat EV71 infection. However, development of these drugs and vaccines is vital to protect younger generations. This study aims to develop a specific monoclonal antibody (mAb) to EV71 using a plant platform, which is a cost-effective and scalable production technology. A previous report showed that D5, a murine anti-EV71 mAb, binds to VP1 protein of EV71, potently neutralizes EV71 in vitro, and effectively protects mice against EV71 infection. Herein, plant-produced chimeric D5 (cD5) mAb, variable regions of murine D5 antibody linked with constant regions of human IgG1, was transiently expressed in Nicotiana benthamiana using geminiviral vectors. The antibody was expressed at high levels within six days of infiltration. Plant-produced cD5 retained its in vitro high-affinity binding and neutralizing activity against EV71. Furthermore, a single dose (10 µg/g body weight) of plant-produced cD5 mAb offered 100% protection against infection in mice after a lethal EV71 challenge. Therefore, our results showed that plant-produced anti-EV71 mAb is an effective, safe, and affordable therapeutic option against EV71 infection. Full article
(This article belongs to the Special Issue Plant Expression Systems for Bioproduct Production)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Plant-produced anti-Enterovirus 71 (EV71) monoclonal antibody efficiently protects mice against EV71 infection

Author: Waranyoo Phoolcharoen

Abstract: Enterovirus 71 (EV71) is the causative agents of sever hand-foot-mouth disease. EV71 mainly affects the countries in Asia-Pacific region, which is not attractive for drug companies to develop EV71 drug or vaccine. Considering the lack of a vaccine antiviral drug against EV71, the development of these drugs and vaccines is the top priority in protecting the young generations. This study aims to develop the monoclonal antibody (mAb) specific to EV71 from the plant platform, which is cost-efficient and scalable production technology. Previous report showed that D5, a murine anti-EV71 mAb, binds to VP1 protein of EV71, blocks viral fusion, and effectively protects mice against EV71 infection. Herein, plant-produced D5 mAb was transiently expressed in Nicotiana benthamiana using Geminiviral vectors. The antibody was expressed at high level within 6 days of infiltration and retained high affinity binding and potent neutralizing activity in vitro against EV71. A single dose of plant D5 protected mice against EV71. This study demonstrates the efficacy of plant-produced mAb against EV71 lethal infection in animal challenge model.

Back to TopTop